1SXP — SCHOTT Pharma AG & Co KgaA Share Price
- €3.57bn
- €3.64bn
- €957.09m
- 64
- 11
- 15
- 17
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 20.82 | ||
PEG Ratio (f) | 1.81 | ||
EPS Growth (f) | 13.04% | ||
Dividend Yield (f) | 0.78% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.3 | ||
Price to Tang. Book | 4.47 | ||
Price to Free Cashflow | 78.03 | ||
Price to Sales | 3.74 | ||
EV to EBITDA | 15.55 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 16.67% | ||
Return on Equity | 17.32% | ||
Operating Margin | 18.21% |
Financial Summary
Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | 584.23 | 648.67 | 821.14 | 898.6 | 957.09 | 1,018.76 | 1,137.68 | 13.13% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | +30.71 | +32.7 | +9.7 | +1.97 | +2.86 | +20.51 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
SCHOTT Pharma AG & Co. KGaA is a Germany-based company. The Company is primarily engaged in designing advanced drug containment solutions and drug delivery systems for the pharmaceutical and biotech industries. The Company’s portfolio ranges from syringes and cartridges to vials and ampoules, all made using Type I Borosilicate Glass and high-grade pharmaceutical polymer.
Directors
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 10th, 2022
- Public Since
- September 28th, 2023
- No. of Employees
- 4,689
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
XETRA
- Shares in Issue
- 150,614,616

- Address
- Hattenbergstrasse 10, MAINZ, 55122
- Web
- https://www.schott-pharma.com/
- Phone
- +49 6131660
- Contact
- Jasko Terzic
- Auditors
- Ernst & Young GmbH
Upcoming Events for 1SXP
Q3 2025 SCHOTT Pharma AG & Co KgaA Earnings Release
Similar to 1SXP
Aap Implantate AG
XETRA
Bio-Gate AG
XETRA
FAQ
As of Today at 23:06 UTC, shares in SCHOTT Pharma AG & Co KgaA are trading at €23.70. This share price information is delayed by 15 minutes.
Shares in SCHOTT Pharma AG & Co KgaA last closed at €23.70 and the price had moved by -39.26% over the past 365 days. In terms of relative price strength the SCHOTT Pharma AG & Co KgaA share price has underperformed the FTSE Global All Cap Index by -40.78% over the past year.
The overall consensus recommendation for SCHOTT Pharma AG & Co KgaA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe SCHOTT Pharma AG & Co KgaA dividend yield is 0.68% based on the trailing twelve month period.
Last year, SCHOTT Pharma AG & Co KgaA paid a total dividend of €0.16, and it currently has a trailing dividend yield of 0.68%. We do not have any data on when SCHOTT Pharma AG & Co KgaA is to next pay dividends.
We do not have data on when SCHOTT Pharma AG & Co KgaA is to next pay dividends. The historic dividend yield on SCHOTT Pharma AG & Co KgaA shares is currently 0.68%.
To buy shares in SCHOTT Pharma AG & Co KgaA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €23.70, shares in SCHOTT Pharma AG & Co KgaA had a market capitalisation of €3.57bn.
Here are the trading details for SCHOTT Pharma AG & Co KgaA:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: 1SXP
Based on an overall assessment of its quality, value and momentum SCHOTT Pharma AG & Co KgaA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SCHOTT Pharma AG & Co KgaA is €28.40. That is 19.83% above the last closing price of €23.70.
Analysts covering SCHOTT Pharma AG & Co KgaA currently have a consensus Earnings Per Share (EPS) forecast of €1.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SCHOTT Pharma AG & Co KgaA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -24.67%.
As of the last closing price of €23.70, shares in SCHOTT Pharma AG & Co KgaA were trading -14.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SCHOTT Pharma AG & Co KgaA PE ratio based on its reported earnings over the past 12 months is 20.82. The shares last closed at €23.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on SCHOTT Pharma AG & Co KgaA's directors